Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$36.73
+1.4%
$30.85
$23.69
$36.82
$16.08B0.68898,617 shs247,981 shs
10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
+0.66%+1.97%+19.51%+29.24%+23.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.2425 of 5 stars
1.03.02.50.02.70.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.00
Hold$28.00-23.77% Downside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$5.81B2.77$3.22 per share11.39$12.64 per share2.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$412M$2.1616.9918.361.10N/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.892.42%N/A41.20%N/A

Latest ANII, SNN, BHMU, and TFG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
semi-annual$0.28502.1%10/3/202510/3/202511/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.60
3.00
1.40

Institutional Ownership

CompanyInstitutional Ownership
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%

Insider Ownership

CompanyInsider Ownership
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
17,349437.98 million433.60 millionOptionable

Recent News About These Companies

Smith & Nephew: US bank upbeat after meetings with management
Smith & Nephew: Doing Better And Still Offers Value
Smith+Nephew jumps 14% on earnings beat and buyback
Smith & Nephew: Quiet start for med-tech giant as pressure mounts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$36.73 +0.50 (+1.38%)
As of 02:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.